Evaluation of an oral direct factor Xa inhibitor anticoagulant in healthy adult horses.

This research aimed to examine whether a commonly used human anticoagulant drug, at its lower recommended dosage, could provide effective blood clot prevention in horses without inducing any bleeding. The study concluded that the drug did not achieve the desired therapeutic plasma concentration in horses, suggesting more research is needed to determine the optimal dosage.

Methodology of the Study

• The study was an experimental one in which ten healthy adult horses were administered the anticoagulant drug known as an oral direct factor Xa inhibitor (DiXaI).
• This drug was given once daily for four days at a dosage of 0.125 mg/kg. After a two-week wash-out period, eight out of the ten horses were given daily subcutaneous injections of a separate anticoagulant (low molecular weight heparin or dalteparin) at a dosage of 50 IU/kg for four successive days.
• Throughout both parts of the study, antifactor Xa activity (which measures the effectiveness of the anticoagulant) was measured both before dose administration and three hours after.
• Other blood health parameters such as activated partial thromboplastin time, prothrombin time, hematocrit, erythrocyte agglutination, and platelet aggregation were also monitored.
• An in vitro spiking experiment was performed alongside the main study. This involved adding the DiXaI to horse plasma in a laboratory setting to further evaluate its anticoagulant activity.

Study Findings

• The study determined that the horses did not achieve the recommended therapeutic range of antifactor Xa activity (0.1-0.2 IU/mL) when given the DiXaI, except for one horse after the drug’s first administration. In contrast, the plasma antifactor Xa activity of the horses given dalteparin fell within the desired range, with a median value of 0.16 IU/mL.
• Importantly, no bleeding events or erythrocyte agglutination were reported. This shows that while the drug’s anticoagulant effect might have been less than desired, it didn’t lead to negative side effects.
• The in vitro spiking experiment demonstrated that the DiXaI has a concentration-dependent effect on antifactor Xa activity in horse plasma.

Conclusions and Implications

• From these findings, the researchers concluded that this dosage of the oral formulation of DiXaI, while on the low end of the dose recommended for people, did not reach the prophylactic plasma antifactor Xa activity in the group of healthy adult horses.
• This suggests that further studies are necessary to establish a more effective prophylactic dose for horses. The findings are crucial, as they could impact bleeding prevention strategies in veterinary care, specifically in equine practice.